Growth hormone in children with idiopathic short stature
The distribution within the group was wide. Compiling the results of the studies suggests an average growth gain of 3 cm to 7 cm. It has not been established that growth hormone treatment reduces behavioral disorders and problems at school during childhood, or that treatment leads to a higher qualit...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Stockholm
Swedish Council on Health Technology Assessment (SBU)
2003, 2003
|
| Edition: | Version 2.0 |
| Series: | SBU alert report
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The distribution within the group was wide. Compiling the results of the studies suggests an average growth gain of 3 cm to 7 cm. It has not been established that growth hormone treatment reduces behavioral disorders and problems at school during childhood, or that treatment leads to a higher quality of life in adulthood. The rate of side effects from growth hormone treatment in children is low. Known, but uncommon, side effects include edema and diabetes. Ethical aspects: Two important factors have ethical implications. First, one may question whether it is ethically defensible to subject healthy children to daily treatment for an extended period, with uncertain individual benefits. Second, the issue arises as to whether short stature in otherwise healthy individuals should be classified as a disease, or whether treatment that promotes growth in this group should be classified as "cosmetic". Technology and target group: When it became possible to synthetically produce growth hormone in the mid 1980s, a debate arose concerning whether short children without growth hormone deficiency, i.e., idiopathic short stature (ISS), would benefit from treatment. Growth hormone treatment for ISS is based on two assumptions, i.e., that treatment will increase final height and that short stature leads to psychological suffering. Treatment is administered by daily injections and may often continue for about 10 years. Currently, ISS is not an approved indication for growth hormone treatment. The number of children seeking treatment for ISS in Sweden is estimated at 500 to 1,000 per year. Patient benefit: In six controlled and two non-controlled studies, children with ISS received growth hormone treatment and were followed until they reached final height. The average effect of treatment on final height varies substantially among the studies, ranging from 2 cm to 9 cm. Hence, whether growth hormone treatment of children with ISS should be considered to be a task for health care should therefore be the subject of further discussions on prioritizations of medical needs versus resource allocation. Economic aspects: The cost-effectiveness of growth hormone treatment in ISS has been estimated in a meta-analysis and in an economic evaluation from the National Health Service Research & Development Health Technology Assessment Programme. Scientific evidence: There is moderate scientific documentation concerning the patient benefits derived from treatment of idiopathic short stature. There is poor scientific documentation on the cost-effectiveness of the method |
|---|---|
| Item Description: | Caption title |
| Physical Description: | 1 PDF file (9 pages) |